No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
(-)-trans-delta-9-tetrahydrocannabinol |
Dronabinol |
D00306 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
1件: 13 |
2 |
(im) avonex® |
- |
- |
- |
- |
1件: 13 |
3 |
(r) 3-(5-dimethylcarbamoyl-pent-1-enyl)-n-(2-hydroxy-1- methylethyl) benzamide |
Pentaerythritol tetranitrate |
D01721 |
- |
- |
1件: 13 |
4 |
0,5 mg fingolimod |
Fingolimod |
D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
5 |
0.25mg rpc1063 |
- |
- |
- |
- |
1件: 13 |
6 |
1 - andrographis paniculata p/st extract |
- |
- |
- |
- |
1件: 13 |
7 |
1% steroid cream |
- |
- |
- |
- |
1件: 13 |
8 |
1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1h-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone |
- |
- |
- |
- |
1件: 13 |
9 |
1.0mg rpc1063 |
- |
- |
- |
- |
1件: 13 |
10 |
10 milligram (mg) fampridine-sr (4-aminopyridine, 4-ap) |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
11 |
10000iu vitamin d |
Vitamin d |
- |
- |
- |
1件: 13 |
12 |
11c-acetate |
Acetate |
- |
- |
- |
3件: 13, 86, 88 |
13 |
11c-pib |
- |
- |
- |
- |
1件: 13 |
14 |
13-pcv booster |
- |
- |
- |
- |
1件: 13 |
15 |
13-valent pneumococcal conjugate vaccine (13-pcv) |
- |
- |
- |
- |
1件: 13 |
16 |
15 mg fampridine-sr (4-aminopyridine, 4-ap) |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
17 |
18f-dpa-714 and 18f-fdg |
Fludeoxyglucose f-18 |
- |
- |
- |
1件: 13 |
18 |
18f-fdg |
Fludeoxyglucose f-18 |
- |
- |
- |
7件: 6, 13, 46, 53, 84, 127, 300 |
19 |
19 nor vitamin d |
Vitamin d |
- |
- |
- |
1件: 13 |
20 |
2 - excipients |
- |
- |
- |
- |
1件: 13 |
21 |
2-cda |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
22 |
2-cda, 2-chloro-2’-deoxy-beta-d-adenosine |
Adenosine |
D00045 |
4件: ADORA1, ADORA2A, ADORA2B, ADORA3 |
12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 13 |
23 |
2-cda, 2-chloro-2’-deoxy-ß-d-adenosine |
Adenosine |
D00045 |
4件: ADORA1, ADORA2A, ADORA2B, ADORA3 |
12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 13 |
24 |
2-chloro-2'-deoxyadenosine, 2cda |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
25 |
2-chloro-2’-deoxyadenosine (2-cda) |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
26 |
20 mg fampridine-sr (4-aminopyridine, 4-ap) |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
27 |
20 mg ga |
- |
- |
- |
- |
1件: 13 |
28 |
200106 or emd 28162 |
- |
- |
- |
- |
1件: 13 |
29 |
20mg/0.5ml ga |
- |
- |
- |
- |
1件: 13 |
30 |
20mg/0.5ml glatiramer acetate |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
31 |
23-ppv |
- |
- |
- |
- |
1件: 13 |
32 |
23-valent pneumococcal polysaccharide vaccine |
- |
- |
- |
- |
3件: 13, 46, 53 |
33 |
23-valent pneumococcal polysaccharide vaccine (23-ppv) |
- |
- |
- |
- |
1件: 13 |
34 |
25oh-vitamin d |
Vitamin d |
- |
- |
- |
1件: 13 |
35 |
2b3-201 |
- |
- |
- |
- |
1件: 13 |
36 |
2cda |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
37 |
3 mg melatonin |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
1件: 13 |
38 |
3,4-diaminopyridine |
- |
- |
- |
- |
3件: 11, 12, 13 |
39 |
4-aminopyridine |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
2件: 3, 13 |
40 |
4-ap |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
41 |
4.5 mg naltrexone |
Naltrexone |
D02095, D05113 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
1件: 13 |
42 |
40 mg ga |
- |
- |
- |
- |
2件: 2, 13 |
43 |
40 mg glatiramer acetate |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
2件: 2, 13 |
44 |
5 mg melatonin |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
1件: 13 |
45 |
5000iu vitamin d |
Vitamin d |
- |
- |
- |
1件: 13 |
46 |
52069.00.01 |
- |
- |
- |
- |
1件: 13 |
47 |
9060x |
- |
- |
- |
- |
2件: 13, 149 |
48 |
95% pure ecgc capsules 200mg |
- |
- |
- |
- |
1件: 13 |
49 |
[11c]flumazenil |
Flumazenil |
D00697 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 13 |
50 |
[123i]clinde |
- |
- |
- |
- |
2件: 6, 13 |
51 |
[14c]-rpc1063 solution (0.1 mg/ml) for oral administration |
- |
- |
- |
- |
3件: 13, 96, 97 |
52 |
[18f] pbr06 |
- |
- |
- |
- |
2件: 6, 13 |
53 |
[18f]-feppa |
- |
- |
- |
- |
2件: 6, 13 |
54 |
[18f]dpa-714 |
- |
- |
- |
- |
1件: 13 |
55 |
[18f]florbetapir and pet imaging |
- |
- |
- |
- |
1件: 13 |
56 |
[c-11]methylreboxetine |
- |
- |
- |
- |
1件: 13 |
57 |
[f-18]pbr06 |
- |
- |
- |
- |
1件: 13 |
58 |
[zr-89]oxine-labeled leukocytes pet/mr |
Oxyquinoline |
D05321 |
- |
- |
1件: 13 |
59 |
A4i antagonist |
- |
- |
- |
- |
1件: 13 |
60 |
Ab1010 |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
61 |
Abatacept |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
24件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
62 |
Abobotulinumtoxin a |
- |
- |
- |
- |
1件: 13 |
63 |
Abr-215062 sodium salt |
- |
- |
- |
- |
2件: 13, 96 |
64 |
Abt-555 |
- |
- |
- |
- |
1件: 13 |
65 |
Abt-874/human monoclonal antibody against il-12 |
- |
- |
- |
- |
1件: 13 |
66 |
Abx-1431 hcl |
- |
- |
- |
- |
1件: 13 |
67 |
Acetaminophen |
Acetaminophen |
D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
11件: 13, 34, 35, 46, 49, 51, 70, 86, 231, 256, 271 |
68 |
Acetaminophen tab 650mg |
Acetaminophen |
D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
1件: 13 |
69 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
70 |
Acetazolamide |
Acetazolamide |
D00218, D01196 |
13件: CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9 |
7件: Bile secretion, Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Nitrogen metabolism, Pancreatic secretion, Proximal tubule bicarbonate reclamation |
6件: 13, 90, 115, 155, 225, 230 |
71 |
Acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
14件: 6, 13, 19, 20, 49, 51, 58, 85, 94, 111, 164, 233, 298, 299 |
72 |
Acetylsalicylic acid |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
3件: 13, 46, 51 |
73 |
Acetylsalicylic acid at 1st visit, |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
1件: 13 |
74 |
Aclasta |
Zoledronic acid |
D01968, D06378, D06379, D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
3件: 13, 271, 274 |
75 |
Aclasta 5 mg infusionslösung |
Zoledronic acid |
D01968, D06378, D06379, D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |
76 |
Aclasta 5mg solution for infusion |
Zoledronic acid |
D01968, D06378, D06379, D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 13 |
77 |
Act-128800 |
Ponesimod |
D11215 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
78 |
Act-128800 dose 1 |
Ponesimod |
D11215 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
79 |
Act-128800 dose 2 |
Ponesimod |
D11215 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
80 |
Act-128800 dose 3 |
Ponesimod |
D11215 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 13 |
81 |
Acth |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
5件: 13, 66, 145, 193, 222 |
82 |
Acthar |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
6件: 2, 13, 46, 49, 50, 222 |
83 |
Acthar gel |
- |
- |
- |
- |
4件: 13, 46, 49, 84 |
84 |
Acthar gel (acth) |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 13 |
85 |
Active comparator receiving extavia® |
- |
- |
- |
- |
1件: 13 |
86 |
Active control |
- |
- |
- |
- |
1件: 13 |
87 |
Actos (pioglitazone) |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
1件: 13 |
88 |
Acyclovir |
Acyclovir |
D00222 |
- |
- |
2件: 13, 28 |
89 |
Adderall xr |
- |
- |
- |
- |
1件: 13 |
90 |
Adderall xr 10 mg |
- |
- |
- |
- |
1件: 13 |
91 |
Adderall xr 5mg |
- |
- |
- |
- |
1件: 13 |
92 |
Adenosine |
Adenosine |
D00045 |
4件: ADORA1, ADORA2A, ADORA2B, ADORA3 |
12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 13, 58, 65 |
93 |
Adrenocorticotropic hormone |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
3件: 13, 50, 84 |
94 |
Adrenocorticotropic hormone (acth) gel (h.p. acthar®) |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 13 |
95 |
Ads-5102 |
- |
- |
- |
- |
2件: 6, 13 |
96 |
Ads-5102, 137 mg |
- |
- |
- |
- |
1件: 13 |
97 |
Ads-5102, 274 mg |
- |
- |
- |
- |
1件: 13 |
98 |
Aert, (r)-baclofen |
Baclofen |
D00241 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
99 |
Agee cream |
- |
- |
- |
- |
1件: 13 |
100 |
Aimspro |
- |
- |
- |
- |
2件: 13, 51 |
101 |
Ain457 |
- |
- |
- |
- |
7件: 13, 37, 41, 46, 56, 96, 271 |
102 |
Alanine |
L-alanine |
D00012 |
- |
- |
3件: 13, 298, 299 |
103 |
Albumin (human) 25%, united states pharmacopeia (usp) |
- |
- |
- |
- |
2件: 13, 14 |
104 |
Albuterol |
Salbutamol |
D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
8件: 12, 13, 86, 89, 113, 231, 256, 299 |
105 |
Alcohol |
Ethanol |
D00068, D02798, D04855, D06542 |
- |
- |
4件: 13, 58, 279, 298 |
106 |
Alemtuzumab |
Alemtuzumab |
D02802 |
- |
- |
13件: 13, 15, 19, 20, 46, 51, 60, 63, 65, 85, 96, 164, 284 |
107 |
Alemtuzumab (gz402673) |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
108 |
Alemtuzumab 12 mg |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
109 |
Alemtuzumab 24 mg |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
110 |
Alemtuzumab gz402673 |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
111 |
Alemtuzumab immunotherapy |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
112 |
Alemtuzumab injection [lemtrada] |
Alemtuzumab |
D02802 |
- |
- |
1件: 13 |
113 |
Alfuzosin |
Alfuzosin |
D01692, D07124 |
1件: ADRA1A |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 13 |
114 |
Alks 8700 |
- |
- |
- |
- |
1件: 13 |
115 |
Alks 8700 delayed release (dr) |
- |
- |
- |
- |
1件: 13 |
116 |
Alks 8700 delayed release (dr) capsule |
- |
- |
- |
- |
1件: 13 |
117 |
Allogeneic human umbilical cord tissue-derived mesenchymal stem cells |
- |
- |
- |
- |
1件: 13 |
118 |
Alpha lipoic acid |
Lipoic acid |
D00048, D00086 |
- |
- |
1件: 13 |
119 |
Alpha-lipoic acid |
Lipoic acid |
D00048, D00086 |
- |
- |
2件: 2, 13 |
120 |
Alpha1-antitrypsin |
- |
- |
- |
- |
1件: 13 |
121 |
Altri farmaci del sistema nervoso |
- |
- |
- |
- |
1件: 13 |
122 |
Amantadine |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
4件: 6, 8, 13, 127 |
123 |
American ginseng |
Ginseng |
D06772 |
- |
- |
1件: 13 |
124 |
American ginseng extract ht-1001 |
Ginseng |
D06772 |
- |
- |
1件: 13 |
125 |
Amiloride |
Amiloride |
D00649, D07447 |
3件: SCNN1A, SCNN1B, SCNN1G |
2件: Aldosterone-regulated sodium reabsorption, Taste transduction |
3件: 13, 225, 299 |
126 |
Amiloride hydrochloride |
Amiloride |
D00649, D07447 |
3件: SCNN1A, SCNN1B, SCNN1G |
2件: Aldosterone-regulated sodium reabsorption, Taste transduction |
1件: 13 |
127 |
Amiloride hydrochloride, 2 h2o |
Amiloride |
D00649, D07447 |
3件: SCNN1A, SCNN1B, SCNN1G |
2件: Aldosterone-regulated sodium reabsorption, Taste transduction |
1件: 13 |
128 |
Amilostad hct |
- |
- |
- |
- |
1件: 13 |
129 |
Amilostad hct tablets |
- |
- |
- |
- |
1件: 13 |
130 |
Ampyra |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
131 |
An100226 |
- |
- |
- |
- |
2件: 13, 96 |
132 |
An100226, bg00002 |
- |
- |
- |
- |
1件: 13 |
133 |
Anakinra |
Anakinra |
D02934 |
2件: IL1R1, IL1R2 |
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
15件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 84, 86, 106, 107, 299 |
134 |
Androgel 1 % topical gel |
- |
- |
- |
- |
1件: 13 |
135 |
Androgel 100mg gel |
- |
- |
- |
- |
1件: 13 |
136 |
Andrographolides |
- |
- |
- |
- |
1件: 13 |
137 |
Anesthetic topical adhesive synera |
- |
- |
- |
- |
1件: 13 |
138 |
Anti lp40 antibody, subclass igg4 la294 |
- |
- |
- |
- |
2件: 13, 46 |
139 |
Anti-cd25 humanized monoclonal antibody |
- |
- |
- |
- |
1件: 13 |
140 |
Anti-cd52 monoclonal antibody |
- |
- |
- |
- |
1件: 13 |
141 |
Anti-il-12 |
- |
- |
- |
- |
2件: 13, 96 |
142 |
Anti-thymocyte globulin |
- |
- |
- |
- |
18件: 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 |
143 |
Anticholinergic medication |
- |
- |
- |
- |
1件: 13 |
144 |
Antihistamine |
- |
- |
- |
- |
2件: 13, 46 |
145 |
Antimycotic |
- |
- |
- |
- |
1件: 13 |
146 |
Antithymocyte |
- |
- |
- |
- |
1件: 13 |
147 |
Antithymocyte immunoglobulin (rabbit) |
Rabbit |
- |
- |
- |
2件: 13, 65 |
148 |
Arbaclofen |
Arbaclofen |
D09791 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
2件: 13, 206 |
149 |
Arbaclofen er tablets |
Arbaclofen |
D09791 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
150 |
Arbaclofen extended release tablets |
Arbaclofen |
D09791 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
151 |
Arbaclofen placarbil |
Arbaclofen placarbil |
D08861 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
152 |
Arbaclofen placarbil 15 mg bid |
Arbaclofen placarbil |
D08861 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
153 |
Arbaclofen placarbil 30 mg bid |
Arbaclofen placarbil |
D08861 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
154 |
Arbaclofen placarbil 45 mg bid |
Arbaclofen placarbil |
D08861 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
155 |
Aricept |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
4件: 6, 13, 78, 124 |
156 |
Aricept 10 mg |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 13 |
157 |
Aricept 10 mg filmdragerade tabletter |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 13 |
158 |
Aricept 5 mg |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 13 |
159 |
Aricept 5 mg filmdragerade tabletter |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 13 |
160 |
Arm 1 - geh120714 (18f) injection |
- |
- |
- |
- |
1件: 13 |
161 |
Armodafinil |
Armodafinil |
D03215 |
1件: SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
3件: 6, 13, 84 |
162 |
Arn-6039 |
- |
- |
- |
- |
1件: 13 |
163 |
Arzerra |
Ofatumumab |
D09314 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 13 |
164 |
Asb-683699 |
- |
- |
- |
- |
1件: 13 |
165 |
Aspartate |
Aspartic acid |
D00013 |
- |
- |
3件: 13, 75, 299 |
166 |
Aspirin |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
10件: 13, 22, 34, 46, 49, 51, 86, 113, 158, 231 |
167 |
Aspirin 650mg oral capsule |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
1件: 13 |
168 |
Ata188 |
- |
- |
- |
- |
1件: 13 |
169 |
Atacicept |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
4件: 13, 46, 49, 66 |
170 |
Atacicept 150 mg |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
3件: 13, 49, 66 |
171 |
Atacicept 25 mg |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
2件: 13, 66 |
172 |
Atacicept 75 mg |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
3件: 13, 49, 66 |
173 |
Atl1102 |
Atl1102 |
- |
- |
- |
1件: 13 |
174 |
Atomoxetine |
Atomoxetine |
D02574, D07473 |
1件: SLC6A2 |
1件: Synaptic vesicle cycle |
3件: 6, 8, 13 |
175 |
Atorvastatin |
Atorvastatin |
D00258, D00887, D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
176 |
Atx-ms-1467 |
- |
- |
- |
- |
1件: 13 |
177 |
Aubagio |
Teriflunomide |
D10172 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
1件: 13 |
178 |
Aubagio - 14 mg - compressa rivestita con film - uso orale - blister (alu/alu) - 28 compresse |
Teriflunomide |
D10172 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
1件: 13 |
179 |
Aubagio® |
- |
- |
- |
- |
1件: 13 |
180 |
Autologous adipose derived mesenchymal cells |
- |
- |
- |
- |
1件: 13 |
181 |
Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved |
- |
- |
- |
- |
1件: 13 |
182 |
Autologous bone marrow-derived mononuclear stem cells |
- |
- |
- |
- |
1件: 13 |
183 |
Autologous cd4+t cells stimulated and expanded ex vivo by a mog peptide modified by the introduction of a thioreductase motif into the flanking residues of the t cell epitope |
- |
- |
- |
- |
1件: 13 |
184 |
Autologous hematopoietic stem cell |
- |
- |
- |
- |
1件: 13 |
185 |
Autologous mesenchymal cell product |
- |
- |
- |
- |
1件: 13 |
186 |
Autologous mesenchymal stem cell transplantation |
- |
- |
- |
- |
1件: 13 |
187 |
Autologous mesenchymal stem cells |
- |
- |
- |
- |
5件: 2, 6, 13, 17, 46 |
188 |
Autologous stem cells |
- |
- |
- |
- |
2件: 13, 51 |
189 |
Autologous t-lymphocytes |
- |
- |
- |
- |
1件: 13 |
190 |
Autologous vitd3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (toldc-vitd3) |
- |
- |
- |
- |
1件: 13 |
191 |
Av605 |
- |
- |
- |
- |
1件: 13 |
192 |
Avonex |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
2件: 13, 97 |
193 |
Avonex (interferon beta 1a) |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
194 |
Avonex (interferon beta-1a), biogen idec ltd |
Human interferon beta |
- |
- |
- |
1件: 13 |
195 |
Avonex 30 µg/0,5 ml solution for injection |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
196 |
Avonex and topamax |
- |
- |
- |
- |
1件: 13 |
197 |
Avonex im 4sir 30mcg/0,5ml 4ag |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
198 |
Avonex/betaseron/copaxone/rebif |
- |
- |
- |
- |
1件: 13 |
199 |
Avonex/zocor |
- |
- |
- |
- |
1件: 13 |
200 |
Avonex® |
- |
- |
- |
- |
1件: 13 |
201 |
Avonex® monotherapy (6.0 miu administered i.m. each week) |
- |
- |
- |
- |
1件: 13 |
202 |
Avp-923 |
- |
- |
- |
- |
3件: 2, 6, 13 |
203 |
Azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
18件: 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
204 |
Azatioprina |
Azathioprine |
D00238, D03033 |
- |
- |
3件: 13, 96, 97 |
205 |
Azatioprina hex. 50cpr 50mg bl |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 13 |
206 |
Azithromycin |
Azithromycin |
D02134, D06390, D07486 |
- |
- |
6件: 13, 84, 85, 96, 228, 299 |
207 |
Bacille calmette-guerin vaccine |
- |
- |
- |
- |
1件: 13 |
208 |
Bacille of calmette-guerin |
- |
- |
- |
- |
1件: 13 |
209 |
Baclofen |
Baclofen |
D00241 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
5件: 2, 10, 13, 18, 149 |
210 |
Baclofen 20 mg |
Baclofen |
D00241 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
211 |
Baclofen ir |
Baclofen |
D00241 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
212 |
Baf312 |
- |
- |
- |
- |
2件: 13, 50 |
213 |
Baf312 0,25 mg tablet |
- |
- |
- |
- |
1件: 13 |
214 |
Baf312 1 mg tablet |
- |
- |
- |
- |
2件: 13, 50 |
215 |
Baf312 4 mg tablet |
- |
- |
- |
- |
1件: 13 |
216 |
Baf312 hemifumarate |
- |
- |
- |
- |
2件: 13, 50 |
217 |
Baf312a |
- |
- |
- |
- |
1件: 13 |
218 |
Bafiertam |
- |
- |
- |
- |
1件: 13 |
219 |
Balance |
Isoxaflutole |
- |
- |
- |
8件: 5, 6, 13, 18, 81, 113, 149, 299 |
220 |
Baminercept |
Baminercept |
D08866 |
1件: LTB |
3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis |
4件: 13, 46, 53, 97 |
221 |
Baseline treatment |
- |
- |
- |
- |
1件: 13 |
222 |
Bat4406f |
- |
- |
- |
- |
1件: 13 |
223 |
Bay 79-4998 |
- |
- |
- |
- |
1件: 13 |
224 |
Bay86-5046 |
- |
- |
- |
- |
1件: 13 |
225 |
Bay86-5046_interferon-beta-1b |
- |
- |
- |
- |
1件: 13 |
226 |
Bazedoxifene |
Bazedoxifene |
D03062 |
- |
- |
1件: 13 |
227 |
Bazedoxifene acetate |
Bazedoxifene |
D03062 |
- |
- |
1件: 13 |
228 |
Bbr 2778 |
- |
- |
- |
- |
2件: 11, 13 |
229 |
Bcd-033 (interferon beta 1a) |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
230 |
Bcd-054 180 mcg |
- |
- |
- |
- |
1件: 13 |
231 |
Bcd-054 240 mcg |
- |
- |
- |
- |
1件: 13 |
232 |
Bcd-063 |
- |
- |
- |
- |
1件: 13 |
233 |
Bcd-132 |
- |
- |
- |
- |
1件: 13 |
234 |
Bcg20-0134 |
- |
- |
- |
- |
1件: 13 |
235 |
Beam |
Tricyclazole |
- |
- |
- |
1件: 13 |
236 |
Beam regimen |
Tricyclazole |
- |
- |
- |
1件: 13 |
237 |
Beetainterferoni -1a |
- |
- |
- |
- |
1件: 13 |
238 |
Best available therapy (bat) |
- |
- |
- |
- |
1件: 13 |
239 |
Beta interferon |
Human interferon beta |
- |
- |
- |
1件: 13 |
240 |
Beta-1b interferoni |
- |
- |
- |
- |
1件: 13 |
241 |
Beta-alanine |
L-alanine |
D00012 |
- |
- |
1件: 13 |
242 |
Beta-alanine supplementation |
L-alanine |
D00012 |
- |
- |
1件: 13 |
243 |
Beta-carotene |
Beta carotene |
D03101 |
- |
- |
1件: 13 |
244 |
Beta-interferon |
Human interferon beta |
- |
- |
- |
1件: 13 |
245 |
Betacarotene |
Beta carotene |
D03101 |
- |
- |
1件: 13 |
246 |
Betaferon |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
247 |
Betaferon 250 microgram/ml |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
248 |
Betaferon 250 microgram/ml, powder and solvent for solution for injection |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
249 |
Betaferon 250µg |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
250 |
Betaferon 500mcg |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
251 |
Betaferon 500µg |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
252 |
Betaferon sc 15f 0,25mg 15sir |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
253 |
Betaferon*15confez 0,25mg/ml+ |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
254 |
Betaferon, bay 86-5046 |
- |
- |
- |
- |
1件: 13 |
255 |
Betaferon/betaseron |
- |
- |
- |
- |
1件: 13 |
256 |
Betaferon® |
- |
- |
- |
- |
1件: 13 |
257 |
Betaferon® (interferon beta-1b) |
Human interferon beta |
- |
- |
- |
1件: 13 |
258 |
Betaseron |
Interferon beta-1b |
D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
259 |
Betaseron (interferon beta-1b, bay86-5046) |
Human interferon beta |
- |
- |
- |
1件: 13 |
260 |
Betaseron (interferon beta-1b, bay86-5046), bayer healthcare ag |
Human interferon beta |
- |
- |
- |
1件: 13 |
261 |
Betmiga |
Mirabegron |
D09535 |
1件: ADRB3 |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cGMP-PKG signaling pathway |
1件: 13 |
262 |
Bevacizumab |
Bevacizumab |
D06409 |
1件: VEGFA |
21件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
263 |
Bexarotene |
Bexarotene |
D03106 |
3件: RXRA, RXRB, RXRG |
15件: Adipocytokine signaling pathway, Bile secretion, Gastric cancer, Hepatitis C, Non-alcoholic fatty liver disease (NAFLD), Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer |
2件: 13, 75 |
264 |
Bg00002 |
- |
- |
- |
- |
1件: 13 |
265 |
Bg00002 (natalizumab) |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
266 |
Bg00002-e (natalizumab high titer) |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
267 |
Bg00012 |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
2件: 13, 46 |
268 |
Bg00012 (dmf) |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 13 |
269 |
Bg00012 (dmf) (tecfidera®.) |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 13 |
270 |
Bg0002 (natalizumab) |
Natalizumab |
D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
271 |
Bg9418 (interferon beta 1-a) |
Interferon beta-1a |
D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
272 |
Bg9418 (interferon beta-1a) |
Human interferon beta |
- |
- |
- |
2件: 13, 97 |
273 |
Bgg492 |
- |
- |
- |
- |
1件: 13 |
274 |
Bht-3009 |
- |
- |
- |
- |
1件: 13 |
275 |
Bht-3009 0.5 mg |
- |
- |
- |
- |
1件: 13 |
276 |
Bht-3009 1.5 mg |
- |
- |
- |
- |
1件: 13 |
277 |
Bht-3009-01 |
- |
- |
- |
- |
1件: 13 |
278 |
Biib017 |
- |
- |
- |
- |
1件: 13 |
279 |
Biib017 (peginterferon beta-1a) |
- |
- |
- |
- |
1件: 13 |
280 |
Biib019 |
- |
- |
- |
- |
1件: 13 |
281 |
Biib019 (daclizumab) |
Daclizumab |
D03639 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
1件: 13 |
282 |
Biib033 |
- |
- |
- |
- |
1件: 13 |
283 |
Biib033 (anti-lingo) |
- |
- |
- |
- |
1件: 13 |
284 |
Biib033 (opicinumab) |
Opicinumab |
- |
- |
- |
1件: 13 |
285 |
Biib041 |
- |
- |
- |
- |
1件: 13 |
286 |
Biib041 (fampridine) |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
287 |
Biib041 (fampridine-sr) |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
288 |
Biib041 (pr fampridine) |
Dalfampridine |
D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
1件: 13 |
289 |
Biib061 |
- |
- |
- |
- |
1件: 13 |
290 |
Biotin |
Biotin |
D00029 |
- |
- |
3件: 2, 13, 20 |
291 |
Birt 2584 xx |
- |
- |
- |
- |
1件: 13 |
292 |
Bisacodyl |
Bisacodyl |
D00245 |
- |
- |
1件: 13 |
293 |
Blood sample |
- |
- |
- |
- |
12件: 8, 13, 46, 49, 51, 53, 61, 66, 97, 274, 288, 299 |
294 |
Blood samples |
- |
- |
- |
- |
8件: 13, 41, 46, 51, 61, 97, 227, 271 |
295 |
Blood sampling |
- |
- |
- |
- |
4件: 13, 19, 51, 96 |
296 |
Bmmnc |
- |
- |
- |
- |
2件: 13, 57 |
297 |
Bms 188667 (abatacept) |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
1件: 13 |
298 |
Bone marrow autologous mesenchymal stem cells transplantation |
- |
- |
- |
- |
1件: 13 |
299 |
Borage oil |
Borage oil |
- |
- |
- |
1件: 13 |
300 |
Borage oil 20% gla |
Borage oil |
- |
- |
- |
1件: 13 |
301 |
Bosentan |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
9件: 13, 41, 47, 51, 84, 85, 86, 88, 210 |
302 |
Boswelan |
- |
- |
- |
- |
1件: 13 |
303 |
Boswellia serrata |
Indian frankincense |
- |
- |
- |
1件: 13 |
304 |
Boswellia serrata extract |
Indian frankincense |
- |
- |
- |
1件: 13 |
305 |
Boswellia serrata extract ps0201bo capsules |
Indian frankincense |
- |
- |
- |
1件: 13 |
306 |
Boswellic acids (boswelan) |
- |
- |
- |
- |
1件: 13 |
307 |
Botox |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
4件: 6, 13, 149, 226 |
308 |
Botox® |
- |
- |
- |
- |
1件: 13 |
309 |
Botulinum toxin a |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
4件: 13, 51, 149, 226 |
310 |
Botulinum toxin a - haemagglutinin complex |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
1件: 13 |
311 |
Botulinum toxin type a |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
10件: 2, 5, 6, 7, 13, 15, 17, 70, 113, 149 |
312 |
Bx-1 |
- |
- |
- |
- |
1件: 13 |
313 |
C1-esterase inhibitor (cinryze) |
- |
- |
- |
- |
1件: 13 |
314 |
C105 |
- |
- |
- |
- |
1件: 13 |
315 |
Calcio |
Calcium |
- |
- |
- |
1件: 13 |
316 |
Calcio folinato dc.it |
Calcium |
- |
- |
- |
1件: 13 |
317 |
Calcium |
Calcium |
- |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
318 |
Calcium carbonate |
Calcium carbonate |
D00932, D10802 |
- |
- |
7件: 13, 19, 46, 75, 96, 235, 299 |
319 |
Calcium levofolinate |
Calcium |
- |
- |
- |
1件: 13 |
320 |
Cannabidiol |
Cannabidiol |
D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
13件: 6, 13, 46, 95, 96, 97, 140, 144, 145, 157, 158, 193, 271 |
321 |
Cannabidiol / dronabinol capsule 5 mg+2,5 mg |
Cannabidiol |
D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
1件: 13 |
322 |
Cannabidiol capsule 5 mg |
Cannabidiol |
D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
1件: 13 |
323 |
Cannabis |
Medical cannabis |
- |
- |
- |
6件: 2, 6, 13, 90, 96, 97 |
324 |
Cannabis based medicine extract (sativex) |
Medical cannabis |
- |
- |
- |
1件: 13 |
325 |
Cannabis, medical |
Medical cannabis |
- |
- |
- |
5件: 2, 6, 13, 96, 97 |
326 |
Cannador |
- |
- |
- |
- |
1件: 13 |
327 |
Caprylic triglyceride |
Tricaprylin |
- |
- |
- |
1件: 13 |
328 |
Capsules with 160 mg teavigo (at least 94% egcg) |
Epigallocatechin gallate |
- |
- |
- |
1件: 13 |
329 |
Carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
8件: 2, 4, 6, 13, 17, 90, 164, 201 |
330 |
Carbonate |
Carbonate ion |
- |
- |
- |
10件: 2, 13, 17, 19, 46, 75, 96, 127, 235, 299 |
331 |
Carmustine |
Carmustine |
D00254 |
- |
- |
5件: 11, 13, 14, 28, 60 |
332 |
Carmustine, etoposide, cytarabine, and melphalan (beam) |
Carmustine, Cytarabine |
D00168, D00254, D03046, D03637 |
- |
- |
1件: 13 |
333 |
Carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
8件: 5, 13, 58, 96, 97, 265, 298, 316 |
334 |
Carnosine |
Carnosine |
- |
- |
- |
2件: 6, 13 |
335 |
Carnosine, capsulle, 2 g/day, 8 weeks |
Carnosine |
- |
- |
- |
1件: 13 |
336 |
Cci-779 |
- |
- |
- |
- |
2件: 13, 46 |
337 |
Cdp323 |
Cdp323 |
- |
- |
- |
1件: 13 |
338 |
Cellular therapy with ebv specific autologous ctl infusion |
- |
- |
- |
- |
1件: 13 |
339 |
Ceralifimod |
- |
- |
- |
- |
1件: 13 |
340 |
Ceralifmod |
- |
- |
- |
- |
1件: 13 |
341 |
Cesamet™ (nabilone) |
Nabilone |
D05099 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
1件: 13 |
342 |
Ceterizine |
- |
- |
- |
- |
1件: 13 |
343 |
Cetirizina |
Cetirizine |
D00664, D07662 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 13 |
344 |
Cetirizina mylan generics |
Cetirizine |
D00664, D07662 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 13 |
345 |
Cetirizine |
Cetirizine |
D00664, D07662 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
2件: 13, 35 |
346 |
Cetirizine hydrochloride |
Cetirizine |
D00664, D07662 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 13 |
347 |
Cgp 77116 |
- |
- |
- |
- |
1件: 13 |
348 |
Charcoal |
Activated charcoal |
D03251 |
- |
- |
1件: 13 |
349 |
Chloride |
Chloride ion |
- |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
350 |
Cholecalciferol |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
9件: 13, 19, 34, 46, 49, 96, 97, 298, 299 |
351 |
Cholecalciferol, vitamin d3 |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 13 |
352 |
Cholestyramine |
Cholestyramine |
- |
- |
- |
2件: 13, 79 |
353 |
Chr-1103 / gbr500 |
- |
- |
- |
- |
1件: 13 |
354 |
Cianocobalamina |
Cyanocobalamin |
D00166, D03615, D03616, D03617 |
- |
- |
1件: 13 |
355 |
Cianocobalamina fu dc.it |
Cyanocobalamin |
D00166, D03615, D03616, D03617 |
- |
- |
1件: 13 |
356 |
Ciclofosfamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
1件: 13 |
357 |
Circadin |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
1件: 13 |
358 |
Circadin ( inn= melatonin) |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
1件: 13 |
359 |
Cisapride |
Cisapride |
D00274, D02092 |
3件: HTR2A, HTR3A, HTR4 |
7件: Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
1件: 13 |
360 |
Cladribine |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
2件: 13, 94 |
361 |
Cladribine 3.5 mg/kg |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
362 |
Cladribine 5.25 mg/kg |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
363 |
Cladribine tablets |
Cladribine |
D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 13 |
364 |
Clemastine |
Clemastine |
D00666, D03535 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 13 |
365 |
Clostridium botulinum |
Clostridium botulinum |
- |
- |
- |
1件: 13 |
366 |
Clostridium botulinum toxin type a |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
1件: 13 |
367 |
Cnm-au8 |
- |
- |
- |
- |
2件: 2, 13 |
368 |
Cnp-ms-0601 |
- |
- |
- |
- |
1件: 13 |
369 |
Cnto 1275 |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
2件: 13, 96 |
370 |
Co-14 |
- |
- |
- |
- |
1件: 13 |
371 |
Coconut |
Coconut |
- |
- |
- |
1件: 13 |
372 |
Coconut oil |
Coconut oil |
D05326 |
- |
- |
1件: 13 |
373 |
Coconut oil and epigallocatechin gallate |
Epigallocatechin gallate |
- |
- |
- |
1件: 13 |
374 |
Coenzyme q |
- |
- |
- |
- |
1件: 13 |
375 |
Colecalciferol |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
4件: 13, 46, 96, 228 |
376 |
Colecalciferol concentrate (oily form) |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 13 |
377 |
Control |
Chloroxylenol |
D03473 |
- |
- |
4件: 6, 13, 46, 168 |
378 |
Cop-1 |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
379 |
Cop-1/copolymer-1 |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
380 |
Copaxone |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
381 |
Copaxone 20 mg/ml |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
382 |
Copaxone 20 mg/ml solution for injection, pre-filled syringe |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
383 |
Copaxone 40 mg/ml solution for injection, pre-filled syringe |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
384 |
Copaxone subcutaneous injection syringe |
- |
- |
- |
- |
1件: 13 |
385 |
Copaxone-teva |
- |
- |
- |
- |
1件: 13 |
386 |
Copaxone® |
- |
- |
- |
- |
1件: 13 |
387 |
Copolymer 1 |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
388 |
Copolymer-1 |
Glatiramer |
D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
1件: 13 |
389 |
Corticosteroid |
- |
- |
- |
- |
10件: 13, 42, 43, 44, 45, 66, 84, 96, 97, 222 |
390 |
Corticosteroids & tancart19/20 |
- |
- |
- |
- |
1件: 13 |
391 |
Corticotropin |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
7件: 2, 13, 46, 75, 78, 84, 222 |
392 |
Cranberry |
Cranberry |
- |
- |
- |
1件: 13 |
393 |
Creatine |
Creatine |
- |
- |
- |
12件: 1, 2, 5, 6, 8, |